enGene Holdings Inc. Common Stock (ENGN)

enGene Holdings Inc. Common Stock (ENGN) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $119M; returns 1 day -1.3%, 1 week -6.6%, 1 year -80.2%.

enGene Holdings Inc. (ENGN) is a clinical-stage biotechnology company focused on developing non-viral genetic medicines for urological cancers, particularly non-muscle invasive bladder cancer (NMIBC). Their lead product candidate is detalimogene voraplasmid, a non-viral gene therapy currently in a Phase 2 pivotal LEGEND trial for BCG-unresponsive NMIBC with carcinoma in situ (CIS).

Groups ENGN belongs to

• Biotechnology
• Clinical Stage Biotech
• Canada Companies
• Healthcare
• Oncology
• Gene Therapy
• Clinical Stage
• Biopharmaceutical
• Pharmaceuticals
• Life Sciences
• Immunotherapy

ENGN financial model: income statement, cash flow and balance sheet